{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:34:09Z","timestamp":1715646849942},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,13]]},"DOI":"10.7759\/cureus.60184","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:37:55Z","timestamp":1715596675000},"source":"Crossref","is-referenced-by-count":0,"title":["Isolated Pericardial Effusion Without Associated Myocarditis in a Small-Cell Lung Cancer Patient Undergoing Atezolizumab Therapy"],"prefix":"10.7759","author":[{"given":"Kiara","family":"Jamison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalitha C","family":"Medepalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Star","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13752","article-title":"FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer","volume":"26","author":"Mathieu L","year":"2021","unstructured":"Mathieu L, Shah S, Pai-Scherf L, et al.. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. Oncologist. 2021, 26:433-8. 10.1002\/onco.13752","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.01.013","article-title":"Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors","volume":"123","author":"Palaskas N","year":"2019","unstructured":"Palaskas N, Morgan J, Daigle T, et al.. Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors. Am J Cardiol. 2019, 123:1351-7. 10.1016\/j.amjcard.2019.01.013","journal-title":"Am J Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jead080","article-title":"Erratum: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the Task Force on Cardio-oncology of the European Society of Cardiology (ESC)","volume":"24","year":"2023","unstructured":"Erratum. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the Task Force on Cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J Cardiovasc Imaging. 2023, 24:e98. 10.1093\/ehjci\/jead080","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/HPC.0000000000000327","article-title":"Cardiovascular toxicity associated with immune checkpoint inhibitor therapy: a comprehensive review","volume":"22","author":"Chitsazan M","year":"2023","unstructured":"Chitsazan M, Amin A, Ladel L, Baig A, Chitsazan M. Cardiovascular toxicity associated with immune checkpoint inhibitor therapy: a comprehensive review. Crit Pathw Cardiol. 2023, 22:69-82. 10.1097\/HPC.0000000000000327","journal-title":"Crit Pathw Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205218","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review","volume":"13","author":"Shalata W","year":"2021","unstructured":"Shalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha I, Yakobson A. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Cancers (Basel). 2021, 13:5218. 10.3390\/cancers13205218","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology primer","volume":"3","author":"Zhang L","year":"2021","unstructured":"Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology primer. JACC CardioOncol. 2021, 3:35-47. 10.1016\/j.jaccao.2020.11.012","journal-title":"JACC CardioOncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong J","year":"2021","unstructured":"Gong J, Drobni ZD, Zafar A, et al.. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:e002771. 10.1136\/jitc-2021-002771","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu JR","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019, 115:854-68. 10.1093\/cvr\/cvz026","journal-title":"Cardiovasc Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.08.033","article-title":"Cardiotoxic mechanisms of cancer immunotherapy--a systematic review","volume":"323","author":"Lobenwein D","year":"2021","unstructured":"Lobenwein D, Kocher F, Dobner S, Gollmann-Tepek\u00f6yl\u00fc C, Holfeld J. Cardiotoxic mechanisms of cancer immunotherapy--a systematic review. Int J Cardiol. 2021, 323:179-87. 10.1016\/j.ijcard.2020.08.033","journal-title":"Int J Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"23","author":"Patel RP","year":"2021","unstructured":"Patel RP, Parikh R, Gunturu KS, Tariq RZ, Dani SS, Ganatra S, Nohria A. Cardiotoxicity of immune checkpoint inhibitors. Curr Oncol Rep. 2021, 23:79. 10.1007\/s11912-021-01070-6","journal-title":"Curr Oncol Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.026","article-title":"Immune checkpoint inhibitor-associated pericarditis","volume":"14","author":"Altan M","year":"2019","unstructured":"Altan M, Toki MI, Gettinger SN, et al.. Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol. 2019, 14:1102-8. 10.1016\/j.jtho.2019.02.026","journal-title":"J Thorac Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2019.07.025","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno-oncology","volume":"119","author":"Chen DY","year":"2020","unstructured":"Chen DY, Huang WK, Chien-Chia Wu V, Chang WC, Chen JS, Chuang CK, Chu PH. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno-oncology. J Formos Med Assoc. 2020, 119:1461-75. 10.1016\/j.jfma.2019.07.025","journal-title":"J Formos Med Assoc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000217","article-title":"Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy","volume":"41","author":"de Almeida DV","year":"2018","unstructured":"de Almeida DV, Gomes JR, Haddad FJ, Buzaid AC. Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy. J Immunother. 2018, 41:329-31. 10.1097\/CJI.0000000000000217","journal-title":"J Immunother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon AR","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018, 19:447-58. 10.1016\/S1470-2045(18)30457-1","journal-title":"Lancet Oncol"},{"key":"ref15","unstructured":"FDA. Highlights of prescribing information. atezolizumab. (2020). Accessed: February 10, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761034s033s034s035s036s037s038lbl.pdf."},{"key":"ref16","article-title":"How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy","volume":"9","author":"Ma Y","year":"2019","unstructured":"Ma Y, Wang Q, Dong Q, Zhan L, Zhang J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019, 9:1546-53.","journal-title":"Am J Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/231215-isolated-pericardial-effusion-without-associated-myocarditis-in-a-small-cell-lung-cancer-patient-undergoing-atezolizumab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:38:01Z","timestamp":1715596681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/231215-isolated-pericardial-effusion-without-associated-myocarditis-in-a-small-cell-lung-cancer-patient-undergoing-atezolizumab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.60184","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}